Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1: World distribution of field sampling locations of Aedes aegypti and Aedes mascarensis screened for Wolbachia ... Fig. 1: World distribution of.

Published byAubrey Price Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 1: World distribution of field sampling locations of Aedes aegypti and Aedes mascarensis screened for Wolbachia ... Fig. 1: World distribution of."— Presentation transcript:

1 Fig. 1: World distribution of field sampling locations of Aedes aegypti and Aedes mascarensis screened for Wolbachia ... Fig. 1: World distribution of field sampling locations of Aedes aegypti and Aedes mascarensis screened for Wolbachia in this study. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Entomological Society of America. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Med Entomol, Volume 55, Issue 5, 13 June 2018, Pages 1354–1356, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Fig. 1: World distribution of field sampling locations of Aedes aegypti and Aedes mascarensis screened for Wolbachia ... Fig. 1: World distribution of."

Similar presentations

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Fig. 1. (a) The 10-fold cross validation result of random forest model using an independent population (Austria, ... Fig. 1. (a) The 10-fold cross validation.

Fig. 1. (a) The 10-fold cross validation result of random forest model using an independent population (Austria, ... Fig. 1. (a) The 10-fold cross validation.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.

Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.

Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.
RCTs: randomized controlled ...

RCTs: randomized controlled ...

Similar presentations

Ads by Google